Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group
暂无分享,去创建一个
P. Richardson | F. Baron | I. Yakoub-Agha | D. Blaise | A. Nagler | M. Mohty | M. Aljurf | R. Soiffer | F. Dignan | H. Lazarus | A. Bazarbachi | S. Lachance | G. Basak | P. Bader | C. Peters | F. Ciceri | M. Abecasis | T. Masszi | T. Ruutu | J. Styczyński | B. Savani | W. Saber | J. Dalle | S. Okamoto | A. Pagliuca | F. Petersen | S. Corbacioglu | J. Kuball | M. Michallet | M. Arat | T. Fukuda | A. Alaskar | R. Duarte | E. Aerts | E. Carreras | A. Huynh | F. Malard | M. NíChonghaile | E. Wallhult | Mairéad NíChonghaile
[1] J. Byrd,et al. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. , 2019, Blood.
[2] K. Yoo,et al. Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) , 2019, Bone Marrow Transplantation.
[3] W. Faridi,et al. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[4] J. Sosman,et al. Immune Checkpoint Inhibitor Toxicity in 2018 , 2018, JAMA.
[5] M. Pasquini,et al. Risk Score for the Development of Veno-Occlusive Disease after Allogeneic Hematopoietic Cell Transplant. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[6] M. Carlino,et al. Immune Checkpoint Inhibitor Toxicity , 2018, Current Oncology Reports.
[7] A. Vekhoff,et al. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] P. Richardson,et al. Final results from a defibrotide treatment‐IND study for patients with hepatic veno‐occlusive disease/sinusoidal obstruction syndrome , 2018, British journal of haematology.
[9] A. Seif,et al. The role of peritoneal drainage in veno-occlusive disease in pediatric patients post hematopoietic stem cell transplant , 2018, Bone Marrow Transplantation.
[10] D. Nilsson,et al. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites , 2017, Pediatric blood & cancer.
[11] P. Hari,et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. , 2017, Blood.
[12] P. Richardson,et al. Earlier defibrotide initiation post‐diagnosis of veno‐occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation , 2017, British journal of haematology.
[13] Shannon R. McCurdy,et al. Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Houot,et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. , 2017, Blood.
[15] R. Houot,et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. , 2017, Blood.
[16] K. Myers,et al. Combination of High-Dose Methylprednisolone and Defibrotide for Veno-Occlusive Disease in Pediatric Hematopoietic Stem Cell Transplant Recipients. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[17] P. Richardson,et al. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] M. Liedtke,et al. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.
[19] M. Abecassis,et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation , 2016, Bone Marrow Transplantation.
[20] R. D'Agostino,et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. , 2016, Blood.
[21] S. Giralt,et al. Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[22] T. Miyamoto,et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes , 2016, Bone Marrow Transplantation.
[23] M. Abecassis,et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT) , 2015, Bone Marrow Transplantation.
[24] E. Carreras. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation , 2015, British journal of haematology.
[25] M. Díaz-Ricart,et al. Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[26] K. Myers,et al. High-dose methylprednisolone for veno-occlusive disease of the liver in pediatric hematopoietic stem cell transplantation recipients. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[27] H. Eom,et al. Safety and effects of prophylactic defibrotide for sinusoidal obstruction syndrome in hematopoietic stem cell transplantation. , 2013, Annals of transplantation.
[28] P. Richardson,et al. Drug safety evaluation of defibrotide , 2013, Expert opinion on drug safety.
[29] A. Schulz,et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial , 2012, The Lancet.
[30] M. Díaz-Ricart,et al. Combining allografting with mTOR inhibitors for metastatic renal cell cancer , 2011, Bone Marrow Transplantation.
[31] Allen R. Chen,et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[32] Allen R. Chen,et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[33] M. Aljurf,et al. Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone , 2008, Bone Marrow Transplantation.
[34] M. Terol,et al. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[35] G. Morgan,et al. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease , 2007, Bone Marrow Transplantation.
[36] D. Allan,et al. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[37] H. Im,et al. Prophylactic Low-dose Heparin or Prostaglandin E1 may Prevent Severe Veno-occlusive Disease of the Liver after Allogeneic Hematopoietic Stem Cell Transplantation in Korean Children , 2006, Journal of Korean medical science.
[38] M. Artesani. Anaphylactic shock to defibrotide , 2006, Allergy.
[39] I. Tleyjeh,et al. Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis , 2006, Bone Marrow Transplantation.
[40] B. Chapuis,et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[41] Allen R. Chen,et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. , 2002, Blood.
[42] M. Remberger,et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. , 2002, Blood.
[43] S. Uemoto,et al. A Successful Liver Transplantation for Refractory Hepatic Veno‐Occlusive Disease Originating from Cord Blood Transplantation , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[44] Ha Yeon Lee,et al. A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation , 2002, Bone Marrow Transplantation.
[45] K. Ohashi,et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno‐occlusive disease after stem cell transplantation , 2000, American journal of hematology.
[46] H. Bismuth,et al. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation , 2000, Bone Marrow Transplantation.
[47] Jung Lim Lee,et al. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. , 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[48] D. Neuberg,et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. , 1998, Blood.
[49] N. Callander,et al. Ursodiol Prophylaxis against Hepatic Complications of Allogeneic Bone Marrow Transplantation , 1998, Annals of Internal Medicine.
[50] F. Appelbaum,et al. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation , 1993 .
[51] D. Shen,et al. A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation , 1993, British journal of haematology.
[52] G. Laurent,et al. Prevention of Regimen-Related Toxicities After Bone Marrow Transplantation by Pentoxifylline: A Prospective, Randomized Trial , 1993 .
[53] G. McDonald,et al. Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients , 1993, Annals of Internal Medicine.
[54] A. Grañena,et al. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease , 1993, Annals of Hematology.
[55] P. Bordigoni,et al. PROSTAGLANDIN E1 (PGE1) INDUCED ARTHRITIS FOLLOWING BONE MARROW TRANSPLANTATION , 1991, British journal of haematology.
[56] L. Grochow,et al. VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION , 1987, Transplantation.
[57] Libo Zhao,et al. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis. , 2019, Critical reviews in oncology/hematology.
[58] M. Remberger,et al. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[59] J. Fischer,et al. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. , 2006, Haematologica.
[60] Pankaj Sharma,et al. Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors , 1984, Hepatology.